{
    "pmcid": "8877688",
    "qa_pairs": {
        "How does the VHH E/VHH V nanobody combination affect the spike protein according to the network analysis?": [
            "It induces long-range couplings between different spike protein regions, potentially reducing sensitivity to mutations.",
            "It blocks the ACE2 binding site, preventing viral entry.",
            "It destabilizes the spike protein, leading to its degradation.",
            "It enhances the spike protein's ability to bind to host cell receptors."
        ],
        "What advantage do nanobodies have over traditional antibodies as mentioned in the paper?": [
            "They are smaller and more stable, allowing for multivalent and multi-specific formats.",
            "They have a higher affinity for the ACE2 receptor.",
            "They can directly inhibit viral replication.",
            "They are less expensive to produce."
        ],
        "What is a key strategy for designing effective nanobodies against SARS-CoV-2 variants, as suggested by the study?": [
            "Targeting multiple distinct epitopes to reduce the likelihood of escape mutations.",
            "Focusing on a single high-affinity binding site to maximize neutralization.",
            "Increasing the size of the nanobody to cover more surface area.",
            "Using nanobodies that mimic the ACE2 receptor structure."
        ],
        "What is the primary function of the SARS-CoV-2 spike protein as described in the paper?": [
            "Facilitating viral entry into host cells through interaction with the ACE2 receptor.",
            "Inducing immune response by presenting antigens to host cells.",
            "Inhibiting host cell apoptosis to prolong viral replication.",
            "Transporting viral RNA into the host cell nucleus."
        ],
        "Which mutation in the Omicron variant significantly reduces nanobody binding according to the study?": [
            "E484A mutation.",
            "N501Y mutation.",
            "D614G mutation.",
            "K417N mutation."
        ]
    }
}